Aptamers
2022 Activity indicators
- 4 competitive public projects - ISCIII, MINECO/MICINN
- 1 private led project
- 1 private competitive project led
- 2 competitive HR contracts.
- 8 publications
- IF: 50,994
- D1 publications: 1 (12,5 %)
- Q1 publications: 6 (72 %)
- 1 supervised doctoral thesis read
- Evaluators of projects in national institutions: 3 PIs.
- Evaluators of projects in European institutions: 1 PI.
- Members of editorial committees: 1 PI.
- 7 active Patent families with priority patent:
- P201430955 "TLR4-specific aptamers and their potential use for the treatment of stroke". Entry into national phases in 15 countries
- P201930524 "FPR2 receptor agonist aptamers" with PCT/ES2020/070378 and national phase entry in the USA.
- EP 18 382 888.8 "Aptamers specific against human MNK1 protein and their use in MNK1 detection method and as MNK1 inhibitor" with PCT/EP2019/083547 and national phase entry in Europe and USA.
- EP17382610 "MAFG as a potential therapeutic target to restore chemosensitivity in platinum-resistant cancer cells" with PCTEP2018/06815 extended in USA and Europe.
- EP21382710.8 "Aptamers against the hepatitis c virus core protein" with PCT/EP2022/071188.
- EP22382616.5 "DNA aptamer conjugates recognizing and degrading coronavirus proteins".
- EP22382617.3 "DNA aptamer conjugates recognizing and degrading coronavirus proteins".
- 2 technology licensing agreements signed in the year.
Milestones
- Establishment of multiple collaborations related to aptamer technology.
- Successful award of new competitive public grants: 1) AES22 Personalised Medicine project "Preclinical development of the aptamer apMNKQQ2 targeting MNK1 in gastrointestinal cancer" (PMPTA22/00113); 2) AES22 equipment acquisition grant "Acquisition of equipment for non-invasive fluorescence and proteomic characterisation of tissues" (IFEQ22/00111); 3) first European project in the EU-LAC call of Horzonte Europa entitled "Aptamer-based strategies to create novel biotechnological tools against Arboviruses (ABSarbo)".
- Defence of a doctoral thesis related to the therapeutic use of aptamers by members of the group: "Selection and characterisation of aptamers against histone acetyltransferase 1 (HAT1). Potential therapeutic use in lung cancer".
- Completion of the phase IIa clinical trial of the APTOLL aptamer entitled "First-in-human phase I clinical trial of a TLR4-binding DNA aptamer, ApTOLL: Safety and pharmacokinetics in healthy volunteers", developed by the IRYCIS aptamer group in collaboration with Aptus Biotech, with very promising results.
- Consolidation of the UCS of Aptamers, constituted from the research group and which provides aptamer selection services to IRYCIS and external groups.
Bibliometrics
Articles | Accum. FI | Mean FI | Articles Q1 or Q2 | % in Q1 or Q2 | Articles D1 | % in D1 | |
---|---|---|---|---|---|---|---|
2018 | 6 | 25,6 | 4,27 | 4 | 67 | 2 | 33 |
2019 | 0 | 0,00 | 0,00 | 0 | 0 | 0 | 0 |
2020 | 6 | 24,41 | 4,88 | 5 | 83 | 1 | 17 |
2021 | 6 | 38,28 | 6,38 | 6 | 100 | 1 | 17 |
2022 | 8 | 50,994 | 6,34 | 6 | 75 | 1 | 12,5 |
26 | 139,30 | 4,37 | 21 | 65 | 5 | 16 |
* Only original articles, editorials, guidelines and reviews